Anoro ellipta and Warfarin sodium drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Anoro ellipta (umeclidinium bromide; vilanterol trifenatate) and Warfarin sodium (warfarin sodium). Common drug interactions include pulmonary hypertension among females and drug hypersensitivity among males.

The phase IV clinical study analyzes what interactions people have when they take Anoro ellipta and Warfarin sodium. It is created by eHealthMe based on reports of 67 people who take the same drugs from the FDA, and is updated regularly.

What is Anoro ellipta?

Anoro ellipta has active ingredients of umeclidinium bromide; vilanterol trifenatate. eHealthMe is studying from 16,515 Anoro ellipta users. Check the latest studies of Anoro ellipta.

What is Warfarin sodium?

Warfarin sodium has active ingredients of warfarin sodium. It is often used in atrial fibrillation/flutter. eHealthMe is studying from 71,174 Warfarin sodium users. Check the latest studies of Warfarin sodium.

On Jul, 08, 2026

67 people who take Anoro ellipta and Warfarin sodium together, and have interactions are studied.

Anoro ellipta and Warfarin sodium drug interactions.

What are the common drug interactions of Anoro Ellipta and Warfarin Sodium, by gender? *:

female:

Pulmonary hypertension (increase in blood pressure in the lung artery)
Weight increased
Anaemia (lack of blood)
Asthenia (weakness)
Back injury
Cardiomegaly (increased size of heart than normal)
Chest pain
Haematocrit decreased
Hypoxia (low oxygen in tissues)
Intestinal obstruction

male:

Drug hypersensitivity
Neuralgia (pain in one or more nerves)
Dry mouth
Ulcer
Vomiting
Dyspnoea (difficult or laboured respiration)
Activated partial thromboplastin time prolonged
Anaemia (lack of blood)
Diabetes mellitus (diabetes, caused by a deficiency of the pancreatic hormone insulin)
Drug intolerance (drug sensitivity)

What are the common drug interactions of Anoro Ellipta and Warfarin Sodium, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

n/a

50-59:

Chronic kidney disease
Hyperparathyroidism secondary (an abnormally high concentration of parathyroid hormone in the blood, resulting in weakening of the bones through loss of calcium-secondary)
Nephrogenic anaemia (anaemia due to kidney disease)
Renal failure (kidney dysfunction)

60+:

Drug hypersensitivity
Neuralgia (pain in one or more nerves)
Appendicitis (inflammation of the appendix)
Ascites (accumulation of fluid in the abdominal cavity)
Chronic obstructive pulmonary disease (a progressive disease that makes it hard to breathe)
Dry mouth
Ulcer
Vomiting
Activated partial thromboplastin time prolonged
Death

What are the existing conditions these people have? *

High Blood Cholesterol: 24 people, 35.82%
Chronic Obstructive Pulmonary Disease (a progressive disease that makes it hard to breathe): 20 people, 29.85%
Diabetes: 19 people, 28.36%
Stress And Anxiety: 18 people, 26.87%
Constipation: 18 people, 26.87%
Hyperphosphataemia (electrolyte disturbance in which there is an abnormally elevated level of phosphate in the blood): 17 people, 25.37%
Nausea And Vomiting: 17 people, 25.37%
Bacterial Infection: 17 people, 25.37%
Blood Uric Acid Increased: 17 people, 25.37%
Nausea (feeling of having an urge to vomit): 17 people, 25.37%

* Approximation only. Some reports may have incomplete information.

Do you take Anoro ellipta and Warfarin sodium?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously